Journal of Immunology Research / 2013 / Article / Fig 1

Research Article

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Figure 1

Changes in clinical indices and laboratory tests reflecting disease activity of RA and/or SLE in each case during 24 weeks after abatacept treatment. * , Wilcoxon’s signed-rank test. Comparisons were made against baseline values. RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; CDAI: Clinical Disease Activity Index; HAQ-DI: Health Assessment Questionnaire-Disability Index; SLEDAI: systemic lupus erythematosus disease activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; RF, rheumatoid factor; IgG: immunoglobulin G; Anti-DNA Ab: anti-DNA antibody.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.